Lupin's wholly-owned subsidiary -- Lupin Pharmaceuticals Inc is recalling 7,872 bottles of Rifampin Capsules, a medication used to treat infections caused by bacteria. The company is recalling the affected lot due to Current Good Manufacturing Practice (CGMP) deviations. The drug initiated the Class II recall on July 28 this year.
As per USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
